

November 11, 2021  
SymBio Pharmaceuticals Limited  
(Securities Code: 4582)  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer

## Notice concerning non-operating expenses

SymBio Pharmaceuticals Limited (the “Company”) today announced its non-operating expenses for the third quarter of the fiscal year ending December 31, 2021 (from July 1, 2021 to September 30, 2021).

### 1. Details of Non-operating Expenses

The Company recorded a foreign exchange loss of 887 thousand yen under non-operating expenses for the third quarter of the fiscal year ending December 31, 2021 (from July 1, 2021 to September 30, 2021) due to recent fluctuations in foreign exchange rates. In addition, with a foreign exchange loss of 17,991 thousand yen for the second quarter ended June 30, 2021, a total foreign exchange loss of 18,878 thousand yen was recorded as statements of operations for the first half of the fiscal year ending December 31, 2021.

### 2. Future Outlook

Based on the Company’s assumptions concerning operations for this fiscal year, the Company has determined that this non-operating expense will have no material impact on the results of operations for the year. Accordingly, there is no change to the Company’s financial forecast as a result of this notice. The Company will make a prompt announcement should any revision to its financial forecast be necessary.

### [Contact]

Investor Relations  
Tel: +81(0)3 5472 1125